12/16/2009

Researchers reported in Pediatrics that the investigational drug motavizumab may protect children at high risk for respiratory syncytial virus better than palivizumab. Study data showed motavizumab reduced the risk of RSV hospitalization by 26% and the risk of outpatient RSV-related lower respiratory tract infection by 50%.

Related Summaries